[Osteoporosis - Evidence based therapy].
Osteoporosis therapy has been controversially discussed in the past. In the meantime, several therapeutic options to prevent fractures are available for this disease. With respect to proven fracture benefit, however, the quality of evidence from randomised and controlled clinical trials varies substantially among therapies. From systematic research the best external evidence is available for a supplementation with calcium and vitamin D and a therapy with the bisphosphonates alendronate or risedronate, as well as the SERM raloxifene. For other therapeutic agents like fluorides, vitamin D metabolites, calcitonin and etidronate the quality of evidence is much lower. So far, there is no evidence for other pharmaceutical therapies. Hip protectors are effective in the prevention of hip fractures.
Minne
H W
HW
Institut für Klinische Osteologie "Gustav Pommer" und Klinik "Der Fürstenhof", Bad Pyrmont, Germany. iko_pyrmont@t-online.de
Begerow
B
B
Pfeifer
M
M
D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005459:Fluorides / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D016103:Spinal Fractures / Q000517:prevention & control; D014807:Vitamin D / Q000627:therapeutic use
D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D002116:Calcitonin; D005459:Fluorides; D002118:Calcium
Osteoporose: Umgang mit einer Stoffwechselkrankheit der Knochen unter Berücksichtigung der Prinzipien einer auf Evidenz basierenden Medizin.